<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00801489</url>
  </required_header>
  <id_info>
    <org_study_id>2007-0147</org_study_id>
    <secondary_id>NCI-2012-01659</secondary_id>
    <secondary_id>2007-0147</secondary_id>
    <nct_id>NCT00801489</nct_id>
  </id_info>
  <brief_title>Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome</brief_title>
  <official_title>A Phase 2 Study of Fludarabine, Cytarabine, Filgrastim-sndz,Gemtuzumab Ozogamicin and Idarubicin in Newly Diagnosed Core Binding Factor Associated Acute Myelogenous Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies the side effects and how well fludarabine phosphate, cytarabine,&#xD;
      filgrastim-sndz, gemtuzumab ozogamicin, and idarubicin hydrochloride work in treating&#xD;
      patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome.&#xD;
      Drugs used in chemotherapy, such as fludarabine phosphate, cytarabine, and idarubicin&#xD;
      hydrochloride, work in different ways to stop the growth of cancer cells, either by killing&#xD;
      the cells or by stopping them from dividing. Gemtuzumab ozogamicin is a monoclonal antibody,&#xD;
      called gemtuzumab, linked to a antitumor drug, called calicheamicin. Gemtuzumab is a form of&#xD;
      targeted therapy because it attaches to specific molecules (receptors) on the surface of&#xD;
      cancer cells, known as CD33 receptors, and delivers calicheamicin to kill them.&#xD;
      Colony-stimulating factors, such as filgrastim-sndz, may increase the number of immune cells&#xD;
      found in bone marrow or peripheral blood and may help the immune system recover from the side&#xD;
      effects of chemotherapy. Giving fludarabine phosphate, cytarabine, filgrastim-sndz,&#xD;
      gemtuzumab ozogamicin, and idarubicin hydrochloride may kill more cancer cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Evaluate the safety of a regimen incorporating fludarabine phosphate (fludarabine),&#xD;
      high-dose cytarabine, filgrastim-sndz, gemtuzumab ozogamicin and idarubicin hydrochloride&#xD;
      (idarubicin) in patients with untreated inv(16) or t(8;21) acute myeloid leukemia (AML).&#xD;
&#xD;
      II. Evaluate the complete remission rates achieved in this population with this regimen.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Assess the proportion of patients with untreated inv(16) or t(8;21) AML who, having&#xD;
      entered complete remission (CR) on this regimen, remain alive in CR two years from CR date.&#xD;
&#xD;
      II. Assess whether the quantitative polymerase chain reaction (Q-PCR) results can be used in&#xD;
      detecting relapse in these patients.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      REMISSION INDUCTION: Patients receive filgrastim-sndz subcutaneously (SC) once daily (QD)&#xD;
      beginning on day -1 and continuing until blood count recovery. Patients also receive&#xD;
      fludarabine phosphate intravenously (IV) over 30 minutes on days 1-5, cytarabine IV over 4&#xD;
      hours on days 1-5, gemtuzumab ozogamicin IV over 2 hours on day 1. Patients not in remission&#xD;
      after their first induction therapy may repeat remission induction therapy.&#xD;
&#xD;
      POST-REMISSION THERAPY: Patients receive filgrastim-sndz SC on day -1, fludarabine phosphate&#xD;
      IV over 30 minutes on days 1-3, cytarabine IV over 4 hours on days 1-3, gemtuzumab ozogamicin&#xD;
      IV over 2 hours on day 1 of courses 1 or 2 and 5 or 6, and idarubicin hydrochloride IV over&#xD;
      30 minutes on days 2 and 3 of one post-remission course (post-remission courses 3 or 4)&#xD;
      determined by the treating physician after discussion with the PI if suboptimal qPCR response&#xD;
      (qPCR &gt; 0.01 after post-remission cycle 2 or 3). Treatment repeats every 4-6 weeks for up to&#xD;
      6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      FURTHER MODIFICATION OF POST-REMISSION THERAPY: Patients older than 60, with significant&#xD;
      comorbidities, experiencing life-threatening complications, prolonged cytopenias, or not&#xD;
      achieving complete molecular response may receive decitabine IV over 1 hour daily for 5 days&#xD;
      after discussion with the principal investigator. Treatment repeats every 4-6 weeks for up to&#xD;
      12 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 6 months for 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 4, 2007</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete remission rate</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity rate</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11</condition>
  <condition>Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11</condition>
  <condition>Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1</condition>
  <condition>de Novo Myelodysplastic Syndrome</condition>
  <condition>High Risk Myelodysplastic Syndrome</condition>
  <condition>Inv(16)</condition>
  <condition>Myelodysplastic Syndrome With Excess Blasts</condition>
  <condition>t(16;16)</condition>
  <condition>t(8;21)</condition>
  <condition>Untreated Adult Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment (filgrastim, fludara, cytara, gemtuzu, idarubicin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Detailed Description</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (filgrastim, fludara, cytara, gemtuzu, idarubicin)</arm_group_label>
    <other_name>.beta.-Cytosine arabinoside</other_name>
    <other_name>1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-Beta-D-arabinofuranosylcytosine</other_name>
    <other_name>1.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-</other_name>
    <other_name>Alexan</other_name>
    <other_name>Ara-C</other_name>
    <other_name>ARA-cell</other_name>
    <other_name>Arabine</other_name>
    <other_name>Arabinofuranosylcytosine</other_name>
    <other_name>Arabinosylcytosine</other_name>
    <other_name>Aracytidine</other_name>
    <other_name>Aracytin</other_name>
    <other_name>Aracytine</other_name>
    <other_name>Beta-cytosine Arabinoside</other_name>
    <other_name>CHX-3311</other_name>
    <other_name>Cytarabinum</other_name>
    <other_name>Cytarbel</other_name>
    <other_name>Cytosar</other_name>
    <other_name>Cytosine Arabinoside</other_name>
    <other_name>Cytosine-.beta.-arabinoside</other_name>
    <other_name>Cytosine-beta-arabinoside</other_name>
    <other_name>Erpalfa</other_name>
    <other_name>Starasid</other_name>
    <other_name>Tarabine PFS</other_name>
    <other_name>U 19920</other_name>
    <other_name>U-19920</other_name>
    <other_name>Udicil</other_name>
    <other_name>WR-28453</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (filgrastim, fludara, cytara, gemtuzu, idarubicin)</arm_group_label>
    <other_name>5-Aza-2'-deoxycytidine</other_name>
    <other_name>Aza-TdC</other_name>
    <other_name>Dacogen</other_name>
    <other_name>Decitabine for Injection</other_name>
    <other_name>Deoxyazacytidine</other_name>
    <other_name>Dezocitidine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Filgrastim-sndz</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (filgrastim, fludara, cytara, gemtuzu, idarubicin)</arm_group_label>
    <other_name>Filgrastim Biosimilar Filgrastim-sndz</other_name>
    <other_name>Zarxio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine Phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (filgrastim, fludara, cytara, gemtuzu, idarubicin)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
    <other_name>SH T 586</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemtuzumab Ozogamicin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (filgrastim, fludara, cytara, gemtuzu, idarubicin)</arm_group_label>
    <other_name>Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody</other_name>
    <other_name>CDP-771</other_name>
    <other_name>CMA-676</other_name>
    <other_name>gemtuzumab</other_name>
    <other_name>hP67.6-Calicheamicin</other_name>
    <other_name>Mylotarg</other_name>
    <other_name>WAY-CMA-676</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idarubicin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (filgrastim, fludara, cytara, gemtuzu, idarubicin)</arm_group_label>
    <other_name>4-Demethoxydaunomycin</other_name>
    <other_name>4-demethoxydaunorubicin</other_name>
    <other_name>4-DMDR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (filgrastim, fludara, cytara, gemtuzu, idarubicin)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have untreated AML, or high-risk myelodysplastic syndromes (MDS)&#xD;
             (refractory anemia with excess blasts, [RAEB], or RAEB &quot;in transformation&quot; [RAEB-t])&#xD;
             characterized by t(8;21), inv(16), or t(16;16); the presence of additional&#xD;
             abnormalities is irrelevant&#xD;
&#xD;
          -  Patients must provide written consent&#xD;
&#xD;
          -  Participants will not be excluded based on performance status; for patients with&#xD;
             Eastern Cooperative Oncology Group (ECOG) performance status &gt;= to 3 the dosing&#xD;
             schedule will be discussed with study chairman&#xD;
&#xD;
          -  Patients with organ dysfunction will not be excluded from the study; for patients with&#xD;
             evidence of organ dysfunction (creatinine &gt;= 1.5, cardiac ejection fraction =&lt; 50%,&#xD;
             total bilirubin &gt;=2 and aspartate aminotransferase [AST]/alanine aminotransferase&#xD;
             [ALT] &gt;= 3 times upper limit of normal [ULN]), dose adjustments/omissions will be made&#xD;
&#xD;
          -  Up to one cycle of prior induction therapy will be permitted to include patients in&#xD;
             whom presence of &quot;good-risk&quot; cytogenetics was initially missed; if the patient is in&#xD;
             remission from induction therapy, he/she will receive post-remission therapy; if the&#xD;
             patient is not in remission then he/she will receive induction therapy&#xD;
&#xD;
          -  Patients of child bearing potential should practice effective methods of contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant and lactating females will be excluded&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gautam Borthakur</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gautam Borthakur</last_name>
    <phone>713-563-1586</phone>
    <email>gborthak@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gautam Borthakur</last_name>
      <phone>713-563-1586</phone>
    </contact>
    <investigator>
      <last_name>Gautam Borthakur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 2, 2008</study_first_submitted>
  <study_first_submitted_qc>December 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2008</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Anemia, Refractory, with Excess of Blasts</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
    <mesh_term>Gemtuzumab</mesh_term>
    <mesh_term>Calicheamicins</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

